Machine Learning Predicts Outcomes of Phase III Clinical Trials for Prostate Cancer

Sustainable biofabrication: from bioprinting to AI-driven predictive methods

Biofabrication is potentially an inherently sustainable manufacturing process of bio-hybrid systems based on biomaterials embedded with cell communities. These bio-hybrids promise to augment the sustainability of various human activities, ranging from tissue engineering and robotics to civil engineering and ecology. However, as routine biofabrication practices are laborious and energetically disadvantageous, our society must refine production and validation processes in biomanufacturing. This opinion highlights the research trends in sustainable material selection and biofabrication techniques. By modeling complex biosystems, the computational prediction will allow biofabrication to shift from an error-trial method to an efficient, target-optimized approach with minimized resource and energy consumption. We envision that implementing bionomic rationality in biofabrication will render bio-hybrid products fruitful for greening human activities.

Signals in the Cells: Multimodal and Contextualized Machine Learning Foundations for Therapeutics

Drug discovery AI datasets and benchmarks have not traditionally included single-cell analysis biomarkers. While benchmarking efforts in single-cell analysis have recently released collections of single-cell tasks, they have yet to comprehensively release datasets, models, and benchmarks that integrate a broad range of therapeutic discovery tasks with cell-type-specific biomarkers. Therapeutics Commons (TDC-2) presents datasets, tools, models, and benchmarks integrating cell-type-specific contextual features with ML tasks across therapeutics. We present four tasks for contextual learning at single-cell resolution: drug-target nomination, genetic perturbation response prediction, chemical perturbation response prediction, and protein-peptide interaction prediction. We introduce datasets, models, and benchmarks for these four tasks. Finally, we detail the advancements and challenges in machine learning and biology that drove the implementation of TDC-2 and how they are reflected in its architecture, datasets and benchmarks, and foundation model tooling.

Machine learning in metastatic cancer research: Potentials, possibilities, and prospects

Cancer has received extensive recognition for its high mortality rate, with metastatic cancer being the top cause of cancer-related deaths. Metastatic cancer involves the spread of the primary tumor to other body organs. As much as the early detection of cancer is essential, the timely detection of metastasis, the identification of biomarkers, and treatment choice are valuable for improving the quality of life for metastatic cancer patients. This study reviews the existing studies on classical machine learning (ML) and deep learning (DL) in metastatic cancer research. Since the majority of metastatic cancer research data are collected in the formats of PET/CT and MRI image data, deep learning techniques are heavily involved. However, its black-box nature and expensive computational cost are notable concerns. Furthermore, existing models could be overestimated for their generality due to the non-diverse population in clinical trial datasets. Therefore, research gaps are itemized; follow-up studies should be carried out on metastatic cancer using machine learning and deep learning tools with data in a symmetric manner.

Improving clinical trial design using interpretable machine learning based prediction of early trial termination

This study proposes using a machine learning pipeline to optimise clinical trial design. The goal is to predict early termination probability of clinical trials using machine learning modelling, and to understand feature contributions driving early termination. This will inform further suggestions to the study protocol to reduce the risk of wasted resources. A dataset containing 420,268 clinical trial records and 24 fields was extracted from the ct.gov registry. In addition to study characteristics features, 12,864 eligibility criteria search features are used, generated using a public annotated eligibility criteria dataset, CHIA. Furthermore, disease categorization features are used allowing a study to belong more than one category specified by clinicaltrials.gov. Ensemble models including random forest and extreme gradient boosting classifiers were used to train and evaluate predictive performance. We achieved a Receiver Operator Characteristic Area under the Curve score of 0.80, and balanced accuracy of 0.70 on the test set using gradient boosting classification. We used Shapley Additive Explanations to interpret the termination predictions to flag feature contributions. The proposed pipeline will lead to an optimised clinical trial design and consequently help potentially life-saving treatments reach patients faster.

Bayesian Depth-Wise Convolutional Neural Network Design for Brain Tumor MRI Classification

In recent years, deep learning has been applied to many medical imaging fields, including medical image processing, bioinformatics, medical image classification, segmentation, and prediction tasks. Computer-aided detection systems have been widely adopted in brain tumor classification, prediction, detection, diagnosis, and segmentation tasks. This work proposes a novel model that combines the Bayesian algorithm with depth-wise separable convolutions for accurate classification and predictions of brain tumors. We combine Bayesian modeling learning and Convolutional Neural Network learning methods for accurate prediction results to provide the radiologists the means to classify the Magnetic Resonance Imaging (MRI) images rapidly. After thorough experimental analysis, our proposed model outperforms other state-of-the-art models in terms of validation accuracy, training accuracy, F1-score, recall, and precision. Our model obtained high performances of 99.03% training accuracy and 94.32% validation accuracy, F1-score, precision, and recall values of 0.94, 0.95, and 0.94, respectively. To the best of our knowledge, the proposed work is the first neural network model that combines the hybrid effect of depth-wise separable convolutions with the Bayesian algorithm using encoders.

Considerations for the Use of Machine Learning Extracted Real-World Data to Support Evidence Generation: A Research-Centric Evaluation Framework

A vast amount of real-world data, such as pathology reports and clinical notes, are captured as unstructured text in electronic health records (EHRs). However, this information is both difficult and costly to extract through human abstraction, especially when scaling to large datasets is needed. Fortunately, Natural Language Processing (NLP) and Machine Learning (ML) techniques provide promising solutions for a variety of information extraction tasks such as identifying a group of patients who have a specific diagnosis, share common characteristics, or show progression of a disease. However, using these ML-extracted data for research still introduces unique challenges in assessing validity and generalizability to different cohorts of interest. In order to enable effective and accurate use of ML-extracted real-world data (RWD) to support research and real-world evidence generation, we propose a research-centric evaluation framework for model developers, ML-extracted data users and other RWD stakeholders. This framework covers the fundamentals of evaluating RWD produced using ML methods to maximize the use of EHR data for research purposes.

Editorial for the Special Issue on “Machine Learning in Healthcare and Biomedical Application”

In the last decade, Machine Learning (ML) has indisputably had a pervasive application in healthcare and biomedical applications [...]